CDKN2A and neoplasm: Additional molecular diagnostics (FoundationOne, December 2016) on a tumor sample from the omentum collected during surgery revealed a CDKN2A loss, wild-type TP53, KRAS, NRAS, and BRAF, and a microsatellite stable, mismatch repair proficient, PD-L1-negative tumor with a low mutational burden, indicating that this patient would likely not benefit from immune checkpoint inhibition.